PL3348547T3 - Pochodne benzimidazolu jako inhibitory NAV 1.7 (kanał sodowy, bramkowany napięciem, typ IX, podjednostka alfa (SCN9A)) do leczenia bólu, dysurii i stwardnienia rozsianego - Google Patents
Pochodne benzimidazolu jako inhibitory NAV 1.7 (kanał sodowy, bramkowany napięciem, typ IX, podjednostka alfa (SCN9A)) do leczenia bólu, dysurii i stwardnienia rozsianegoInfo
- Publication number
- PL3348547T3 PL3348547T3 PL16844497T PL16844497T PL3348547T3 PL 3348547 T3 PL3348547 T3 PL 3348547T3 PL 16844497 T PL16844497 T PL 16844497T PL 16844497 T PL16844497 T PL 16844497T PL 3348547 T3 PL3348547 T3 PL 3348547T3
- Authority
- PL
- Poland
- Prior art keywords
- scn9a
- dysuria
- nav
- gated
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015179663 | 2015-09-11 | ||
| PCT/JP2016/076645 WO2017043636A1 (ja) | 2015-09-11 | 2016-09-09 | 新規ベンズイミダゾール化合物およびその医薬用途 |
| EP16844497.4A EP3348547B1 (en) | 2015-09-11 | 2016-09-09 | Benzimidazole derivatives as nav 1.7 (sodium channel, voltage-gated, type ix, alpha subunit (scn9a)) inhibitors for treating pain, dysuria and multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3348547T3 true PL3348547T3 (pl) | 2020-12-14 |
Family
ID=58239905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16844497T PL3348547T3 (pl) | 2015-09-11 | 2016-09-09 | Pochodne benzimidazolu jako inhibitory NAV 1.7 (kanał sodowy, bramkowany napięciem, typ IX, podjednostka alfa (SCN9A)) do leczenia bólu, dysurii i stwardnienia rozsianego |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10407395B2 (pl) |
| EP (1) | EP3348547B1 (pl) |
| JP (1) | JP6768674B2 (pl) |
| KR (1) | KR102654710B1 (pl) |
| CN (1) | CN107922350B (pl) |
| AU (1) | AU2016319597B2 (pl) |
| CA (1) | CA2989992A1 (pl) |
| CY (1) | CY1123482T1 (pl) |
| DK (1) | DK3348547T3 (pl) |
| ES (1) | ES2818529T3 (pl) |
| HU (1) | HUE052395T2 (pl) |
| LT (1) | LT3348547T (pl) |
| PL (1) | PL3348547T3 (pl) |
| PT (1) | PT3348547T (pl) |
| SI (1) | SI3348547T1 (pl) |
| TW (1) | TWI710554B (pl) |
| WO (1) | WO2017043636A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6768674B2 (ja) * | 2015-09-11 | 2020-10-14 | 大日本住友製薬株式会社 | 新規ベンズイミダゾール化合物およびその医薬用途 |
| JP7094942B2 (ja) * | 2017-03-15 | 2022-07-04 | 住友ファーマ株式会社 | ベンズイミダゾール誘導体の製造方法 |
| JP7165501B2 (ja) * | 2017-03-15 | 2022-11-04 | 住友ファーマ株式会社 | 新規ベンズイミダゾール化合物からなる医薬 |
| EP3597639A4 (en) * | 2017-03-15 | 2020-09-16 | Sumitomo Dainippon Pharma Co., Ltd. | BENZIMIDAZOLE DEUTERÉ COMPOUND AND ITS MEDICAL USE |
| KR102183676B1 (ko) | 2018-04-17 | 2020-11-27 | 주식회사 엘지화학 | 타원 편광판 및 유기발광장치 |
| CN115925699B (zh) * | 2022-02-25 | 2023-10-03 | 南京知和医药科技有限公司 | 具有镇痛活性的稠环化合物及其制备方法与用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04010545A (es) * | 2002-04-26 | 2005-01-25 | Pfizer Prod Inc | Inhibidores de metaloproteinasa de heteroariloxi-aril-espiero-pirimidina-2,4,6-triona n-sustituida. |
| KR20060115396A (ko) * | 2003-10-28 | 2006-11-08 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서 유용한 벤즈이미다졸 |
| JP2008501714A (ja) * | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
| EP2582666B1 (en) | 2010-06-16 | 2014-08-13 | Purdue Pharma L.P. | Aryl substituted indoles and their use as blockers of sodium channels |
| JPWO2012057262A1 (ja) | 2010-10-28 | 2014-05-12 | 日本新薬株式会社 | ピリジン誘導体及び医薬 |
| EP2681200A4 (en) * | 2011-03-03 | 2015-05-27 | Zalicus Pharmaceuticals Ltd | INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL |
| WO2012172043A1 (en) * | 2011-06-15 | 2012-12-20 | Laboratoire Biodim | Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections |
| CA2861439C (en) * | 2012-02-03 | 2016-07-12 | Pfizer Inc. | Benzimidazole and imidazopyridine derivatives as sodium channel modulators |
| JPWO2014054635A1 (ja) | 2012-10-02 | 2016-08-25 | 大日本住友製薬株式会社 | イミダゾール誘導体 |
| TW201444820A (zh) | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶ｃｄｋ９激酶抑制劑 |
| JP2016169161A (ja) | 2013-07-19 | 2016-09-23 | 大日本住友製薬株式会社 | 新規イミダゾピリジン化合物 |
| US9828348B2 (en) * | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
| MA40957A (fr) * | 2014-10-09 | 2017-09-19 | Biomarin Pharm Inc | Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies |
| JP2018052817A (ja) * | 2015-01-21 | 2018-04-05 | 大日本住友製薬株式会社 | 新規ベンズイミダゾール誘導体およびその医薬用途 |
| MA41803A (fr) | 2015-03-24 | 2018-01-30 | Almirall Sa | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques |
| JP6786520B2 (ja) | 2015-04-21 | 2020-11-18 | ジーティーエックス・インコーポレイテッド | 選択的アンドロゲン受容体分解剤（ｓａｒｄ）リガンド及びその使用方法 |
| JP6768674B2 (ja) * | 2015-09-11 | 2020-10-14 | 大日本住友製薬株式会社 | 新規ベンズイミダゾール化合物およびその医薬用途 |
-
2016
- 2016-09-09 JP JP2017538545A patent/JP6768674B2/ja active Active
- 2016-09-09 PT PT168444974T patent/PT3348547T/pt unknown
- 2016-09-09 WO PCT/JP2016/076645 patent/WO2017043636A1/ja not_active Ceased
- 2016-09-09 SI SI201630917T patent/SI3348547T1/sl unknown
- 2016-09-09 US US15/323,185 patent/US10407395B2/en active Active
- 2016-09-09 ES ES16844497T patent/ES2818529T3/es active Active
- 2016-09-09 TW TW105129360A patent/TWI710554B/zh active
- 2016-09-09 LT LTEP16844497.4T patent/LT3348547T/lt unknown
- 2016-09-09 DK DK16844497.4T patent/DK3348547T3/da active
- 2016-09-09 KR KR1020187007320A patent/KR102654710B1/ko active Active
- 2016-09-09 CN CN201680052438.1A patent/CN107922350B/zh active Active
- 2016-09-09 HU HUE16844497A patent/HUE052395T2/hu unknown
- 2016-09-09 CA CA2989992A patent/CA2989992A1/en active Pending
- 2016-09-09 EP EP16844497.4A patent/EP3348547B1/en active Active
- 2016-09-09 AU AU2016319597A patent/AU2016319597B2/en active Active
- 2016-09-09 PL PL16844497T patent/PL3348547T3/pl unknown
- 2016-12-30 US US15/395,338 patent/US9688670B2/en active Active
-
2020
- 2020-10-14 CY CY20201100973T patent/CY1123482T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107922350A (zh) | 2018-04-17 |
| KR20180044317A (ko) | 2018-05-02 |
| PT3348547T (pt) | 2020-10-12 |
| HK1251225A1 (en) | 2019-01-25 |
| RU2018105683A3 (pl) | 2019-12-26 |
| TWI710554B (zh) | 2020-11-21 |
| ES2818529T3 (es) | 2021-04-13 |
| JPWO2017043636A1 (ja) | 2018-06-28 |
| AU2016319597A1 (en) | 2018-02-01 |
| TW201713629A (zh) | 2017-04-16 |
| HUE052395T2 (hu) | 2021-04-28 |
| EP3348547A1 (en) | 2018-07-18 |
| WO2017043636A1 (ja) | 2017-03-16 |
| EP3348547B1 (en) | 2020-07-22 |
| KR102654710B1 (ko) | 2024-04-03 |
| US10407395B2 (en) | 2019-09-10 |
| CA2989992A1 (en) | 2017-03-16 |
| CN107922350B (zh) | 2022-04-19 |
| US9688670B2 (en) | 2017-06-27 |
| EP3348547A4 (en) | 2019-03-20 |
| CY1123482T1 (el) | 2022-03-24 |
| RU2018105683A (ru) | 2019-10-14 |
| US20180170881A1 (en) | 2018-06-21 |
| JP6768674B2 (ja) | 2020-10-14 |
| DK3348547T3 (da) | 2020-09-14 |
| US20170107211A1 (en) | 2017-04-20 |
| AU2016319597B2 (en) | 2020-12-24 |
| LT3348547T (lt) | 2020-11-10 |
| SI3348547T1 (sl) | 2020-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258471A (en) | 11,13-modified saxitoxins for the treatment of pain | |
| SI3805233T1 (sl) | (r)in (s) enantiomera n-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo(4,5-b)piridin-6-il) -2-(2-metilpiridin-4-il)oksazol-karboksamid kot inhibitorji irak4 za zdravljenje raka | |
| SI3348547T1 (sl) | Derivati benzimidazola kot zaviralci NAV 1.7 (natrijevi kanalčki, napetostno odvisni, tip IX, podenota alfa (SCN9A)) za zdravljenje bolečine, disurije in multiple skleroze | |
| GB201904104D0 (en) | Composition, method and use | |
| GB2541571A (en) | Pharmaceutical compositions | |
| IL274855A (en) | Device, systems and methods for dental treatments | |
| ZA201904387B (en) | Compositions and methods for treating, ameliorating and preventing h. pylori | |
| GB201504607D0 (en) | Methods,tools and systems for the assessment,preventation,management and treatment selection for type 2 diabetes | |
| GB201705124D0 (en) | Composition, method and use | |
| WO2015171558A3 (en) | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE | |
| SG11201912228WA (en) | Agents, uses and methods for treatment | |
| GB2564511B (en) | Composition, method and use | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| GB2543709A (en) | Pharmaceutical agent | |
| ZA201802399B (en) | Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer | |
| GB201805016D0 (en) | Composition, method and use | |
| IL284980B1 (en) | Heteroaryl-azacyclic-oxo-amide compound, pharmaceutical preparation and pharmaceutical preparation for use in the treatment | |
| GB201819298D0 (en) | New processes, compositions and medical uses | |
| GB2539742B (en) | Therapeutic treatment methods, and apparatus for use therein | |
| ITUB20153493A1 (it) | Attrezzatura per l'applicazione di borchie. | |
| IL274529A (en) | Compounds, compositions, and methods for treating and/or preventing periodontal disease | |
| PL3153022T3 (pl) | N-(3’,4’-dichloro-5-metoksybifenyl-2-ylo)-3-(difluorometylo)-1-metylo-1H-pirazolo-4-karboksyamid | |
| HK40028708A (en) | Agents, uses and methods for treatment | |
| ZA201704287B (en) | 3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of cns disorders | |
| GB2553684B (en) | Ethynylxanthines, preparation and use for cancer treatment |